Prostate specific membrane antigen knockdown impairs the tumorigenicity of LNCaP prostate cancer cells by inhibiting the phosphatidylinositol 3-kinase/Akt signaling pathway

Chinese Medical Journal

Volumn 127, Issue 5, 2014, Pages 929-936

  Guo, Zheng Hui ^a   Lai, Yi Ming ^a   Du, Tao ^a   Zhang, Yi Ming ^a   Chen, Jie Qing ^a   Bi, Liang Kuan ^a   Lin, Tian Xin ^a   Liu, Hao ^a   Wang, Wei ^b   Xu, Ke Wei ^a   Jiang, Chun ^a   Han, Jin Li ^a   Zhang, Cai Xia ^a   Dong, Wen ^a   Huang, Jian ^a   Huang, Hai ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

Author keywords

LNCaP cells; PI3K Akt pathway; Prostate cancer; Prostate specific membrane antigen; RNA interference; Tumorigenicity

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN KINASE B; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN;

ARTICLE; ASSAY; CARCINOGENICITY; CCK 8 ASSAY; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSWELL ASSAY; WESTERN BLOTTING; ENZYMOLOGY; GENETICS; MALE; METABOLISM; PHYSIOLOGY; PROSTATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, SURFACE; CELL LINE, TUMOR; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; PHOSPHATIDYLINOSITOL 3-KINASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84896887153     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20132707     Document Type: Article

References (55)

1. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927-935.
2. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-1811.
3. Chang SS, Gaudin PB, Reuter VE, Heston WD. Prostate-specific membrane antigen: present and future applications. Urology 2000; 55: 622-629.
4. Chang SS. Overview of prostate-specific membrane antigen. Rev Urol 2004; 6: S13-S18.
5. Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PJ, Wang CY, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Sur 2006; 30: 628-636
6. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, et al. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002; 53: 9-23.
7. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle 2008; 7: 2991-2996.
8. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
9. Dbouk HA, Backer JM. A beta version of life: p110beta takes center stage. Oncotarget 2010; 1: 729-733.
10. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-5236.
11. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-1171.
12. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387-390.
13. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A 1999; 96: 4240-4245.
14. Deocampo ND, Huang H, Tindall DJ. The role of PTEN in the progression and survival of prostate cancer. Minerva Endocrinol 2003; 28: 145-153.
15. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, Jiao J, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003; 4: 209-221.
16. Yang G, Ayala G, De Marzo A, Tian W, Frolov A, Wheeler TM, et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8: 3419-3426.
17. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999; 59: 4291-4296.
18. Bedolla R, Prihoda TJ, Kreisberg JI, Malik SN, Krishnegowda NK, Troyer DA, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression and Akt activation. Clin Cancer Res 2007; 13: 3860-3867.
19. Skvortsova I, Skvortsov S, Stasyk T, Raju U, Popper BA, Schiestl B, et al. Intracellular signaling pathways regulating radioresistance of human prostate carcinoma cells. Proteomics 2008; 8: 4521-4533.
20. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62: 6141-6145.
21. Guo Z, Huang H, Zeng L, Du T, Xu K, Lin T, et al. Lentivirus-mediated RNAi knockdown of prostate-specific membrane antigen suppresses growth, reduces migration ability and the invasiveness of prostate cancer cells. Med Oncol 2011; 28: 878-887.
22. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227-230.
23. O'Keefe DS, Su SL, Bacich DJ, Horiguchi Y, Luo Y, Powell CT, et al. Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta 1998; 1443: 113-127.
24. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997; 57: 2321-2324.
25. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007; 50: 472-483.
26. Fair WR, Israeli RS, Heston WD. Prostate-specific membrane antigen. Prostate 1997; 32: 140-148.
27. Wright GJ, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
28. Lu L, Tang D, Wang L, Huang LQ, Jiang GS, Xiao XY, et al. Gambogic acid inhibits TNF-alpha-induced invasion of human prostate cancer PC3 cells in vitro through PI3K/Akt and NF-kappa B signaling pathways. Acta Pharmacol Sin 2012; 33: 531-541.
29. Chang SS, Reuter VE, Heston WD, Gaudin PB. Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology 2001; 57: 1179-1183.
30. Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998; 52: 637-640.
31. Martin GS. Cell signaling and cancer. Cancer Cell 2003; 4: 167-174.
32. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res 2003; 115: 145-167.
33. Zhang W, Yu H, Zou W, Wang YF, Liang XF, Zhang B, et al. Cbl-b and PI3K/Akt pathway are differently involved in oxygen-glucose deprivation preconditioning in PC12 cells. Chin Med J 2013; 126: 4132-4138.
34. Song ZF, Chen DY, Du B, Ji XP. Poly (ADP-ribose) polymerase inhibitor reduces heart ischaemia/reperfusion injury via inflammation and Akt signalling in rats. Chin Med J 2013; 126: 1913-1917.
35. Hughes C, Murphy A, Martin C, Sheils O, O'Leary J. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58: 673-684.
36. Herman SE, Johnson AJ. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 2012; 18: 4013-4018.
37. Denley A, Gymnopoulos M, Kang S, Mitchell C, Vogt PK. Requirement of phosphatidylinositol(3, 4, 5)trisphosphate in phosphatidylinositol 3-kinase-induced oncogenic transformation. Mol Cancer Res 2009; 7: 1132-1138.
38. Sulis ML, Parsons R. PTEN: from pathology to biology. Trend Cell Biol 2003; 13: 478-483.
39. Yoshizaki H, Mochizuki N, Gotoh Y, Matsuda M. Akt-PDK1 complex mediates epidermal growth factor-induced membrane protrusion through Ral activation. Mol Biol Cell 2007; 18: 119-128.
40. Goc A, Al-Husein B, Kochuparambil ST, Liu J, Heston WW, Somanath PR. PI3 kinase integrates Akt and MAP kinase signaling pathways in the regulation of prostate cancer. Int J Oncol 2011; 38: 267-277.
41. Somanath PR, Razorenova OV, Chen J, Byzova TV. Akt1 in endothelial cell and angiogenesis. Cell Cycle 2006; 5: 512-518.
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
43. Mahajna J, Dotan N, Zaidman BZ, Petrova RD, Wasser SP. Pharmacological values of medicinal mushrooms for prostate cancer therapy: the case of Ganoderma lucidum. Nutrit Cancer-An Int J 2009; 61: 16-26.
44. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998; 58: 2720-2723.
45. Koul D, Shen R, Garyali A, Ke LD, Liu TJ, Yung WK. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int J Oncol 2002; 21: 469-475.
46. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A 1998; 95: 5246-5250.
47. Chesire DR, Ewing CM, Gage WR, Isaacs WB. In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 2002; 21: 2679-2694.
48. Li B, Sun A, Youn H, Hong Y, Terranova PF, Thrasher JB, et al. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 2007; 28: 572-583.
49. Wu C, Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. J Biol Chem 2007; 282: 3571-3583.
50. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Curr Cancer Drug Targets 2004; 4: 327-336.
51. Price JT, Thompson EW. Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 2002; 6: 217-233.
52. Zhang Y, Guo Z, Du T, Chen J, Wang W, Xu K, et al. Prostate specific membrane antigen (PSMA): A novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. Prostate 2013; 73: 835-841.
53. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996; 2: 1445-1451.
54. Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004; 91: 528-539.
55. Agell N, Bachs O, Rocamora N, Villalonga P. Modulation of the Ras/Raf/MEK/ERK pathway by Ca(2+), and calmodulin. Cell Signal 2002; 14: 649-654.